Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.

Article  PubMed  Google Scholar 

Chiang YC, Chen CA, Chiang CJ, Hsu TH, Lin MC, You SL, et al. Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. J Gynecol Oncol. 2013;24:342–51.

Article  PubMed  PubMed Central  Google Scholar 

Davis A, Tinker AV, Friedlander M. Platinum resistant ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014;133:624–31.

Article  CAS  PubMed  Google Scholar 

Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, et al. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecol Oncol. 2018;150:239–46.

Article  CAS  PubMed  Google Scholar 

González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381:2391–402.

Article  PubMed  Google Scholar 

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance Olaparib in patients with newly diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379:2495–505.

Article  CAS  PubMed  Google Scholar 

Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31:1606–22.

Article  CAS  PubMed  Google Scholar 

Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16:81–104.

Article  PubMed  PubMed Central  Google Scholar 

Dottino JA, Moss HA, Lu KH, Secord AA, Havrilesky LJ. U.S. Food and Drug Administration-approved poly (ADP-Ribose) polymerase inhibitor maintenance therapy for recurrent ovarian Cancer: a cost-effectiveness analysis. Obstet Gynecol. 2019;133:795–802.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gonzalez R, Havrilesky LJ, Myers ER, Secord AA, Dottino JA, Berchuck A, et al. Cost-effectiveness analysis comparing PARP inhibitors-for-all to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. Gynecol Oncol. 2020;159:483–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107:1776–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chiang YC, Lin PH, Cheng WF. Homologous recombination Deficiency assays in epithelial ovarian Cancer: current status and future direction. Front Oncol. 2021;11:675972.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sztupinszki Z, Diossy M, Krzystanek M, Reiniger L, Csabai I, Favero F, et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. npj Breast Cancer. 2018;4:16.

Article  PubMed  PubMed Central  Google Scholar 

Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, et al. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat Commun. 2020;11:2662.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.

Article  PubMed  Google Scholar 

Lin PH, Chen M, Tsai LW, Lo C, Yen TC, Huang TY, et al. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer. Cancer Sci. 2020;111:1375–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.

Article  PubMed  PubMed Central  Google Scholar 

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.

Article  PubMed  PubMed Central  Google Scholar 

Chiang YC, Lin PH, Lu TP, Kuo KT, Tai YJ, Hsu HC et al. A DNA damage response gene panel for different histologic types of epithelial ovarian carcinomas and their outcomes. Biomedicines 2021;9.

Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2:366–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Popova T, Manié E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012;72:5454–62.

Article  CAS  PubMed  Google Scholar 

Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481:287–94.

Article  CAS  PubMed  Google Scholar 

Watkins JA, Irshad S, Grigoriadis A, Tutt AN. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 2014;16:211.

Article  PubMed  PubMed Central  Google Scholar 

Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus Bevacizumab as First-Line maintenance in Ovarian Cancer. N Engl J Med. 2019;381:2416–28.

Article  CAS  PubMed  Google Scholar 

Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with First-Line Chemotherapy and as maintenance therapy in Ovarian Cancer. N Engl J Med. 2019;381:2403–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18:75–87.

Article  CAS  PubMed  Google Scholar 

Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23:517–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, et al. Homologous recombination Deficiency and Platinum-based therapy outcomes in advanced breast Cancer. Clin Cancer Res. 2017;23:7521–30.

Article  CAS  PubMed  Google Scholar 

Meienberg J, Zerjavic K, Keller I, Okoniewski M, Patrignani A, Ludin K, et al. New insights into the performance of human whole-exome capture platforms. Nucleic Acids Res. 2015;43:e76.

Article  PubMed  PubMed Central